Literature DB >> 7683570

Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.

M S Rhee1, Y Wang, M G Nair, J Galivan.   

Abstract

A subline of H35 hepatoma cells has been developed which exhibits 80-fold resistance to 5,10-dideazatetrahydrofolate, an antifolate which inhibits glycinamideribonucleotide transformylase. The cells are cross-resistant to methotrexate, an inhibitor of dihydrofolate reductase and 10-propargyl-5,8-dideazafolate and its 2-desamino-2-methyl derivative, both inhibitors of thymidylate synthase. The resistant cells are characterized by an impaired activity of the reduced folate transport system which affects cellular import of methotrexate, 5,10-dideazatetrahydrofolate, and 2-desamino-2-methyl-10-propargyl-5,8-dideazafolate but not 10-propargyl-5,8-dideazafolate. In addition, the resistant cells exhibit a severalfold increased activity of gamma-glutamyl hydrolase, the enzyme which cleaves the intracellular polyglutamate derivatives of the antifolates. Evidence for the involvement of gamma-glutamyl hydrolase in resistance is derived from the observation that polyglutamate derivatives of 10-propargyl-5,8-dideazafolate in resistant cells are maintained at one-third the amount of that in parental cells in the presence of the same extracellular concentration. This is the first observation that an increase in gamma-glutamyl hydrolase contributes to acquired resistance to antifolates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683570

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

2.  Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Authors:  Araba A Adjei; Oreste E Salavaggione; Sumithra J Mandrekar; Grace K Dy; Katie L Allen Ziegler; Chiaki Endo; Julian R Molina; Steven E Schild; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

Review 3.  Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance.

Authors:  Shannon Lynn Kordus; Anthony David Baughn
Journal:  Medchemcomm       Date:  2019-05-08       Impact factor: 3.597

4.  Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro.

Authors:  R Yao; E Schneider; T J Ryan; J Galivan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.

Authors:  Garry H Schwartz; Christopher B Jones; Mitchell Garrison; Amita Patnaik; Chris Takimoto; Heather McCreery; Michael Skinner; Anthony W Tolcher; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

6.  Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Authors:  Alex A Adjei; Sumithra J Mandrekar; Grace K Dy; Julian R Molina; Araba A Adjei; David R Gandara; Katie L Allen Ziegler; Philip J Stella; Kendrith M Rowland; Steven E Schild; Ralph G Zinner
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

Review 7.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

8.  Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor.

Authors:  B M O'Connor; S Webber; R C Jackson; J Galivan; M S Rhee
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.

Authors:  Misato Hashizume; Hiroto Yoshida; Keisuke Tanaka; Miho Suzuki; Isao Matsumoto; Takayuki Sumida; Masahiko Mihara
Journal:  Arthritis Res Ther       Date:  2012-04-30       Impact factor: 5.156

10.  The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.

Authors:  E J Estlin; K Balmanno; A H Calvert; A G Hall; J Lunec; D R Newell; A D Pearson; G A Taylor
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.